US biotech firm Biogen Idec (Nasdaq: BIIB) has announced positive top-line results from its Phase II trial of anti-LINGO-1 in acute optic neuritis.
The RENEW trial showed treatment with anti-LINGO-1 demonstrated evidence of biological repair of the visual system, and that it demonstrated an improvement in the recovery of optic nerve latency, which was the study’s endpoint. This was measured by full field visual evoked potential (FF-VEP), relative to placebo.
The study showed no effect on secondary endpoints, including change in thickness of the retinal layers (optic nerve neurons and axons) and visual function, as measured by spectral domain optical coherence tomography (SD-OCT) and low contrast letter acuity, respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze